Kontafarma China Holdings Limited (HKG:1312)

Market Cap	178.83M +6.7%
Revenue (ttm)	914.71M +1.9%
Net Income	-427.85M
EPS	-0.08
Shares Out	5.59B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,578,000
Open	0.0320
Previous Close	0.0320
Day's Range	0.0290 - 0.0330
52-Week Range	0.0200 - 0.0480
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Kontafarma China Holdings

Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediates in Mainland China, Singapore, Taiwan, and internationally. The company operates through Pharmaceutical Business and Fitness Business segments. It provides prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and heal...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 636
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1312

Financial Performance

In 2025, Kontafarma China Holdings's revenue was 914.71 million, an increase of 1.92% compared to the previous year's 897.52 million. Losses were -427.85 million, 466.4% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error